UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 6-K



Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

July, 2019

Commission File Number: 001-38283



InflaRx N.V.



Winzerlaer Str. 2
07745 Jena, Germany
(+49) 3641 508180
(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐



INFLARX N.V.
 
On July 18, 2019, InflaRx N.V. issued a press release titled “InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa.”
 
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jena, Germany, July 18, 2019.

 
INFLARX N.V.
   
 
By:
/s/ Niels Riedemann
 
Name:
Niels Riedemann
 
Title:
Chief Executive Officer

3

EXHIBIT INDEX
 
Exhibit
 
Description of Exhibit
 
Press release dated July 18, 2019


4

InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more InflaRx NV Charts.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more InflaRx NV Charts.